Melissa Eisen

981 total citations
43 papers, 648 citations indexed

About

Melissa Eisen is a scholar working on Hematology, Genetics and Nephrology. According to data from OpenAlex, Melissa Eisen has authored 43 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 16 papers in Genetics and 11 papers in Nephrology. Recurrent topics in Melissa Eisen's work include Platelet Disorders and Treatments (37 papers), Blood groups and transfusion (24 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Melissa Eisen is often cited by papers focused on Platelet Disorders and Treatments (37 papers), Blood groups and transfusion (24 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Melissa Eisen collaborates with scholars based in United States, United Kingdom and Canada. Melissa Eisen's co-authors include James B. Bussel, Adrian C. Newland, Nancy Carpenter, Michael D. Tarantino, Victor S. Blanchette, Jean‐François Viallard, María Fernanda López Fernández, Bertrand Godeau, Amelia Orejudos and Victor Priego and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Melissa Eisen

39 papers receiving 638 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melissa Eisen United States 13 588 122 114 105 91 43 648
Reggie Kelly United States 7 434 0.7× 106 0.9× 94 0.8× 67 0.6× 29 0.3× 9 473
Orna Shamai‐Lubovitz Israel 6 299 0.5× 135 1.1× 65 0.6× 57 0.5× 36 0.4× 11 452
K. Beach United States 4 347 0.6× 47 0.4× 69 0.6× 64 0.6× 39 0.4× 6 471
Stefano Volpetti Italy 12 308 0.5× 220 1.8× 187 1.6× 46 0.4× 11 0.1× 26 538
Thibault Comont France 11 220 0.4× 53 0.4× 145 1.3× 65 0.6× 19 0.2× 54 464
Elly Huiskes Netherlands 15 627 1.1× 57 0.5× 60 0.5× 97 0.9× 271 3.0× 26 702
Thomas Sailer Austria 10 308 0.5× 33 0.3× 31 0.3× 30 0.3× 20 0.2× 14 450
Mathieu Caulier France 9 278 0.5× 67 0.5× 57 0.5× 44 0.4× 22 0.2× 25 368
Wojciech Homenda Poland 6 202 0.3× 147 1.2× 143 1.3× 29 0.3× 17 0.2× 17 349
George T. Conklin United States 3 367 0.6× 83 0.7× 80 0.7× 61 0.6× 29 0.3× 6 410

Countries citing papers authored by Melissa Eisen

Since Specialization
Citations

This map shows the geographic impact of Melissa Eisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Eisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Eisen more than expected).

Fields of papers citing papers by Melissa Eisen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Eisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Eisen. The network helps show where Melissa Eisen may publish in the future.

Co-authorship network of co-authors of Melissa Eisen

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Eisen. A scholar is included among the top collaborators of Melissa Eisen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Eisen. Melissa Eisen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Borges, Giuliano Santos, et al.. (2026). Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. New England Journal of Medicine. 394(11). 1061–1073.
2.
Soff, Gerald A., et al.. (2024). Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature. Cancer Medicine. 13(15). e7429–e7429. 5 indexed citations
3.
McGrath, Leah J., Carrie M. Nielson, Bradley Saul, et al.. (2021). Lessons Learned Using Real‐World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. Clinical Pharmacology & Therapeutics. 110(6). 1570–1578. 4 indexed citations
4.
Nielson, Carrie M., Alexander Breskin, Bradley Saul, et al.. (2021). Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice. Advances in Therapy. 38(5). 2673–2688. 11 indexed citations
5.
6.
Shaw, Jaime L., et al.. (2019). The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States. Platelets. 31(3). 307–314. 16 indexed citations
7.
Tarantino, Michael D., James B. Bussel, Victor S. Blanchette, et al.. (2019). Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Haematologica. 104(11). 2283–2291. 25 indexed citations
8.
Tarantino, Michael D., Jenny M. Despotovic, John D. Grainger, et al.. (2018). Safety and Efficacy of Romiplostim in over 200 Children with Immune Thrombocytopenia (ITP): Results of an Integrated Database of 5 Clinical Trials. Blood. 132(Supplement 1). 2428–2428. 2 indexed citations
9.
Kuter, David J., Adrian C. Newland, Beng H. Chong, et al.. (2017). Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year. Blood. 130. 1055–1055. 1 indexed citations
10.
Cetin, Karynsa, et al.. (2017). Chemotherapy-induced thrombocytopenia (CIT) in metastatic colorectal cancer (mCRC) patients. Annals of Oncology. 28. v202–v202. 1 indexed citations
11.
Cines, Douglas B., Jeffrey S. Wasser, Francesco Rodeghiero, et al.. (2017). Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 102(8). 1342–1351. 44 indexed citations
12.
Tarantino, Michael D., James B. Bussel, Victor S. Blanchette, et al.. (2016). Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP). Blood. 130(22). 14–14. 2 indexed citations
13.
Langeberg, Wendy J., W. Marieke Schoonen, Melissa Eisen, Laurence Gamelin, & Scott Stryker. (2016). Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies. International Journal of Hematology. 103(6). 655–664. 34 indexed citations
14.
Tarantino, Michael D., James B. Bussel, Victor S. Blanchette, et al.. (2016). Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. The Lancet. 388(10039). 45–54. 99 indexed citations
15.
Tarantino, Michael D., et al.. (2016). Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. Platelets. 27(5). 472–478. 17 indexed citations
16.
17.
18.
19.
Tarantino, Michael D., James B. Bussel, Victor S. Blanchette, et al.. (2015). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP). Blood. 126(23). 7–7. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reggie Kelly Breakdown of academic impact, for papers by Orna Shamai‐Lubovitz Breakdown of academic impact, for papers by K. Beach Breakdown of academic impact, for papers by Stefano Volpetti Breakdown of academic impact, for papers by Thibault Comont Breakdown of academic impact, for papers by Elly Huiskes Breakdown of academic impact, for papers by Thomas Sailer Breakdown of academic impact, for papers by Mathieu Caulier Breakdown of academic impact, for papers by Wojciech Homenda Breakdown of academic impact, for papers by George T. Conklin
Rankless by CCL
2026